Portal de Periódicos da CAPES

Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy

2015; Lippincott Williams & Wilkins; Volume: 110; Issue: 9 Linguagem: Inglês

10.1038/ajg.2015.235

1572-0241

Jeremy Lok Wei, Jonathan Chung‐Fai Leung, Thomson Chi‐Wang Loong, Grace Lai–Hung Wong, David Ka‐Wai Yeung, Ruth Chan, Henry Lik‐Yuen Chan, Angel Mei‐Ling Chim, Jean Woo, Chiu‐Wing Winnie Chu, Vincent Wai‐Sun Wong,

Alcohol Consumption and Health Effects

OBJECTIVES: Some studies suggest that non-obese patients with nonalcoholic fatty liver disease (NAFLD) may have more severe disease. We aim to study the epidemiology and severity of non-obese NAFLD. METHODS: A total of 911 community subjects were randomly recruited from the census database of the Hong Kong Government. Intrahepatic triglycerides (IHTG) and liver fibrosis were assessed by proton-magnetic resonance spectroscopy and transient elastography, respectively. The Asian body mass index cutoff of 25 kg/m2 was used to define non-obese NAFLD. RESULTS: The prevalence of NAFLD was 19.3% in non-obese subjects and 60.5% in obese subjects (P<0.001). Compared with obese NAFLD patients, non-obese NAFLD patients had similar IHTG content (median 9.8% vs. 9.9%;P=0.100) but lower cytokeratin-18 fragments (149 vs. 182 IU/l;P=0.019) and liver stiffness (4.6 vs. 5.6 kPa;P<0.001). The G allele at the patatin-like phospholipase domain-containing protein 3 gene (PNPLA3rs738409) was more common in non-obese than obese NAFLD patients (78.4% vs. 59.8%;P=0.001). Obesity, high hemoglobin A1c, insulin resistance, hyperferritinemia, and thePNPLA3G allele were independent factors associated with NAFLD in non-obese subjects. Even among non-obese subjects with normoglycemia, those with NAFLD were more insulin resistant (mean homeostasis model assessment of insulin resistance: 2.0±1.0 vs. 1.1±1.1;P<0.001). CONCLUSIONS: One-fifth of the general non-obese Chinese population has NAFLD. Non-obese patients with NAFLD do not have a higher risk of steatohepatitis or advanced fibrosis. Patients with risk factors of advanced fibrosis such as metabolic syndrome andPNPLA3G allele carriage should be assessed for severe NAFLD.